News
Bausch + Lomb addresses recent IOL recall, ensuring safety with enhanced protocols and returning enVista lenses to market ...
VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback